Welcome to our dedicated page for Codexis SEC filings (Ticker: CDXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Codexis turns its CodeEvolver breakthroughs into revenue isn鈥檛 easy鈥擱&D tax credits, milestone payments, and multi-year licensing deals sprawl across hundreds of pages. If you have ever wondered, 鈥淐odexis SEC filings explained simply,鈥� you are not alone.
Stock Titan鈥檚 AI pinpoints what matters in every document the moment it hits EDGAR. Need the Codexis quarterly earnings report 10-Q filing? We highlight enzyme-sale trends, cash-burn ratios, and collaboration revenue on a single dashboard. Curious about Codexis insider trading Form 4 transactions? AG真人官方-time alerts surface each executive stock move so you can spot patterns before the market reacts.
Our coverage spans every form:
- 10-K: Access the Codexis annual report 10-K simplified with side-by-side AI summaries that flag R&D capitalization, royalty streams, and liquidity notes.
- 10-Q: Drill into quarter-over-quarter enzyme margin shifts through our Codexis earnings report filing analysis.
- 8-K: Material agreements for ECO Synthesis scale-up? See them under Codexis 8-K material events explained.
- Form 4: Follow Codexis executive stock transactions Form 4 with real-time push updates; or search full history via Codexis Form 4 insider transactions real-time.
- DEF 14A: The Codexis proxy statement executive compensation section compares equity grants to peer biotech benchmarks.
Whether you need to model enzyme royalty cash flows, monitor financing covenants, or simply understand Codexis SEC documents with AI, our platform turns dense language into clear, actionable insights鈥攕o you spend minutes, not hours, finding the details that move the stock.
Codexis, Inc. filed a Form S-8 to register an additional 8,000,000 shares of its common stock for issuance under the Codexis, Inc. 2019 Incentive Award Plan, following a stockholder-approved amendment to the plan on June 10, 2025. The filing states these additional shares are in addition to shares registered under prior Form S-8 filings (June 21, 2019 and August 3, 2023), which remain effective, and that the new registration is submitted under General Instruction E to register additional securities of the same class.
The Registration Statement incorporates by reference the company鈥檚 Annual Report for the fiscal year ended December 31, 2024 (filed February 27, 2025), Quarterly Reports for the quarters ended March 31, 2025 (filed May 14, 2025) and June 30, 2025 (filed August 13, 2025), and several Current Reports filed in 2025. The filing also describes the company鈥檚 indemnification provisions for officers and directors and lists exhibits including legal opinions and auditor consents.
Codexis, Inc. reported improved quarterly performance. Total revenue for the three months ended June 30, 2025 was $15.3 million, up from $8.0 million a year earlier, driven by $7.4 million of product sales and $7.9 million of research and development revenue that included a $4.7 million milestone/license recognition. Product gross margin expanded to 72% in the quarter from 45% a year ago, helping reduce the quarterly loss to $13.3 million ($0.16 per share) versus a $22.8 million loss in Q2 2024.
Liquidity and financing: cash and cash equivalents totaled $26.8 million and short-term investments were $39.6 million, for combined cash and short-term investments of $66.3 million, and working capital of $73.5 million. The company has a $40.0 million term loan facility with Innovatus (second $10.0 million tranche funded June 27, 2025) and total long-term debt reported at $39.4 million with an effective interest rate of 12.7% as of June 30, 2025. Operating cash used was $31.8 million for the six months ended June 30, 2025. Codexis continues investment in its ECO Synthesis platform and pharma biocatalysis business.
Aberdeen Group plc and its U.S. affiliate abrdn Inc. jointly filed a Schedule 13G reporting passive ownership of 4,200,950 Codexis (CDXS) common shares as of 30 Jun 2025. The position equals 5.07 % of outstanding stock, making the firms a 5-percent beneficial owner under SEC rules.
The filing states shared voting and dispositive power over the entire stake; neither entity holds sole authority. Aberdeen is classified as a parent holding company/control person (HC) incorporated in the United Kingdom, while abrdn Inc. is a U.S. corporation and registered investment adviser (CO, IA). Both certify the shares were acquired in the ordinary course of business and not to influence control of Codexis.
Signatures were provided by Major Shareholding Reporting Analyst Jenny Clarke on 30 Jul 2025. No exhibits indicate activist intent, group formation, or additional derivatives. The disclosure primarily informs investors of a new institutional holder exceeding the 5 % threshold, adding visibility to Codexis鈥� shareholder base without signaling governance changes.
FAQ
What is the current stock price of Codexis (CDXS)?
What is the market cap of Codexis (CDXS)?
